文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

无创正压通气与气管插管治疗需呼吸支持的COVID-19患者的比较

Non-invasive positive pressure ventilation versus endotracheal intubation in treatment of COVID-19 patients requiring ventilatory support.
PubMed 文献 · Am J Emerg Med · 2021-01-29
一句话结论在需呼吸支持的COVID-19患者中,首选NIV与降低30天全因死亡率相关(OR 0.30),NIV失败后插管者死亡率不劣于首选插管者。

该回顾性研究纳入2020年3-4月纽约布鲁克林一家教学医院的222例需呼吸支持的成人COVID-19确诊患者,分为首选插管、NIV后插管、仅NIV三组。总体30天死亡率77.5%。多因素分析显示仅NIV组死亡率显著低于首选插管组(OR 0.30,95%CI 0.13-0.69),NIV后插管与首选插管无差异。二次分析中所有接受NIV者死亡率低于仅插管者(OR 0.44,95%CI 0.21-0.95)。提示NIV作为初始干预与生存获益相关。

要点

  • 仅NIV组30天全因死亡率69%(95%CI 59-78%),显著低于首选插管组的82%(OR 0.30,95%CI 0.13-0.69)。
  • NIV后插管组死亡率84%(95%CI 70-92%),与首选插管组无差异,提示NIV失败后插管不增加死亡风险。
  • 所有接受NIV者(NIV后插管+仅NIV)死亡率低于仅插管者(OR 0.44,95%CI 0.21-0.95)。
  • 研究为单中心回顾性设计,暴露分组由治疗医师决定,存在选择偏倚可能。
  • 多因素模型校正了年龄、性别、qSOFA≥2、就诊氧饱和度、血管活性药物使用及>3种合并症。

适用人群与场景

  • 成人COVID-19确诊病例,因呼吸衰竭需要呼吸支持(无创通气或气管插管),治疗方式由主治医师决定。
  • 研究场景为纽约布鲁克林一家教学医院2020年3-4月收治的住院患者。

诊断标准与关键阈值

  • 原文未提及具体的NIV启动标准、插管标准或停止阈值。
  • 多因素模型纳入的协变量包括:年龄、性别、qSOFA评分≥2、就诊氧饱和度、血管活性药物使用、>3种合并症。

处置流程与药物剂量

  • 原文未提及具体的NIV模式、参数设置、药物剂量或插管操作流程。
  • 暴露分组定义:首选插管组(初始即气管插管)、NIV后插管组(先接受NIV后插管)、仅NIV组(仅接受无创通气)。

红旗征与不能漏的情况

  • 原文未提及具体的红旗征或需要立即处理的情况。

研究设计与关键结果

  • 研究类型:单中心回顾性研究,纳入222例需呼吸支持的成人COVID-19确诊患者。
  • 主要终点:30天全因死亡率,总体77.5%(95%CI 72-83%)。
  • 首选插管组死亡率82%(95%CI 73-89%;75/91),NIV后插管组84%(95%CI 70-92%;37/44),仅NIV组69%(95%CI 59-78%;60/87)。
  • 多因素分析:仅NIV与降低30天全因死亡率相关(OR 0.30,95%CI 0.13-0.69);NIV后插管与首选插管死亡率无差异。
  • 二次分析:所有接受NIV者(NIV后插管+仅NIV)死亡率低于仅插管者(OR 0.44,95%CI 0.21-0.95)。

证据类型、等级与局限

  • 证据类型:单中心回顾性研究。
  • 局限:回顾性设计、单中心、暴露分组非随机(由治疗医师决定),可能存在选择偏倚;原文未报告不良事件。

对床旁实践的改变

  • 对于需呼吸支持的COVID-19患者,可考虑将NIV作为初始干预而非直接插管,与降低30天死亡率相关。
  • NIV失败后转为插管者的死亡率与首选插管者无差异,提示NIV尝试不增加死亡风险。
  • 研究为回顾性设计,结论需前瞻性验证;原文未提供NIV具体方案或失败标准,临床决策需个体化。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: Initial guidelines recommended prompt endotracheal intubation rather than non-invasive ventilation (NIV) for COVID-19 patients requiring ventilator support. There is insufficient data comparing the impact of intubation versus NIV on patient-centered outcomes of these patients.

OBJECTIVE: To compare all-cause 30-day mortality for hospitalized COVID-19 patients with respiratory failure who underwent intubation first, intubation after NIV, or NIV only.

DESIGN: Retrospective study of patients admitted in March and April of 2020.

SETTING: A teaching hospital in Brooklyn, New York City.

PARTICIPANTS: Adult COVID-19 confirmed patients who required ventilator support (non-invasive ventilation and/or endotracheal intubation) at discretion of treating physician, were included.

EXPOSURES: Patients were categorized into three exposure groups: intubation-first, intubation after NIV, or NIV-only.

PRIMARY OUTCOME: 30-day all-cause mortality, a predetermined outcome measured by multivariable logistic regression. Data are presented with medians and interquartile ranges, or percentages with 95% confidence intervals, for continuous and categorical variables, respectively. Covariates for the model were age, sex, qSOFA score ≥ 2, presenting oxygen saturation, vasopressor use, and greater than three comorbidities. A secondary multivariable model compared mortality of all patients that received NIV (intubation after NIV and NIV-only) with the intubation-first group.

RESULTS: A total of 222 were enrolled. Overall mortality was 77.5% (95%CI, 72-83%). Mortality for intubation-first group was 82% (95%CI, 73-89%; 75/91), for Intubation after NIV was 84% (95%CI, 70-92%; 37/44), and for NIV-only was 69% (95%CI, 59-78%; 60/87). In multivariable analysis, NIV-only was associated with decreased all-cause mortality (odds ratio [OR]: 0.30, 95%CI, 0.13-0.69). No difference in mortality was observed between intubation-first and intubation after NIV. Secondary analysis found all patients who received NIV to have lower mortality than patients who were intubated only (OR: 0.44, 95%CI, 0.21-0.95).

CONCLUSIONS & RELEVANCE: Utilization of NIV as the initial intervention in COVID-19 patients requiring ventilatory support is associated with significant survival benefit. For patients intubated after NIV, the mortality rate is not worse than those who undergo intubation as their initial intervention.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Daniel P, Mecklenburg M, Massiah C, et al. Non-invasive positive pressure ventilation versus endotracheal intubation in treatment of COVID-19 patients requiring ventilatory support. Am J Emerg Med. 2021. PMID: 33550100. doi:10.1016/j.ajem.2021.01.068

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。